Resistance and refractoriness in obsessive-compulsive disorder;Resistência e refratariedade no transtorno obsessivo-compulsivo

Revista Brasileira de Psiquiatria

Volumn 29, Issue SUPPL. 2, 2007, Pages

  Ferrão, Ygor Arzeno ^a,b,e   Diniz, Juliana Belo ^a,c   Lopes, Antônio Carlos ^a,c   Shavitt, Roseli Gedanke ^a,c   Greenberg, Benjamin ^a,d   Miguel, Euripedes ^a,c  

^a Brazilian Research Group on Obsessive Compulsive Disorder   (Brazil)

^b Hospital Psiquiátrico São Pedro   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d BUTLER HOSPITAL   (United States)

^e NONE   (Brazil)

Author keywords

Behavior therapy; Biological psychiatry; Combined modality therapy; Obsessive compulsive disorder; Pychopharmacology

Indexed keywords

CLOMIPRAMINE; CYANOCOBALAMIN; INTRINSIC FACTOR; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR;

ALTERNATIVE MEDICINE; BRAIN DEPTH STIMULATION; DRUG COST; DRUG RESISTANCE; HUMAN; MONOTHERAPY; OBSESSIVE COMPULSIVE DISORDER; PSYCHOTHERAPY; REVIEW; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT RESPONSE;

EID: 37849041039     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1516-44462006005000059     Document Type: Review

References (88)

1. Leckman JF, Grice DE, Boardman J, Zhang H, Vitale A, Bondi C, Alsobrook J, Peterson BS, Cohen DJ, Rasmussen SA, Goodman WK, McDougle CJ, Pauls DL. Symptoms of obsessive-compulsive disorder. Am J Psychiatry. 1997;154(7):911-7.
2. . Fontenelle LF, Mendlowicz MV, Versiani M. The descriptive epidemiology of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(3):327-37.
3. . de Hann E, van Oppen P, van Balkom AJ, Spinhoven P, Hoogduin KA, Van Dyck R. Prediction of outcome and early vs. late improvement in OCD patients treated with cognitive behaviour therapy and pharmacotherapy. Acta Psychiatr Scand. 1997;96(5):354-61.
4. . Shavitt RG, Ferräo YA, Bravo MC, Belotto C, Lopes Junior A, Miguel EC. Transtorno obsessivo-compulsivo resistente: conceito e estratégias de tratamento. Rev Bras Psiquiatr. 2001;23(Supl 2):52-7.
5. Rauch SL, Jenike MA. Managing the patient with treatment resistant Obsessive-Compulsive Disorder: current strategies. J Clin Psychiatry. 1994;55(Suppl):11-7.
6. Rosario-Campos M, Leckman J, Mercadante M, Shavitt RG, Prado HS, Sada P, Zamignani D, Miguel EC, Adults with early-onset obsessive-compulsive disorder. Am J Psychiatry. 2001;158(11):1899-903.
7. Miguel EC, Leckman JF, Rauch S, do Rosario-Campos MC, Hounie AG, Mercadante MT, Chacon P, Pauls DL. Obsessive-compulsive disorder phenotypes: implications for genetic studies. Mol Psychiatry. 2005;10(3):258-75.
8. Erzegovesi S, Cavallini MC, Cavedini P, Diaferia G, Locatelli M, Bellodi L. Clinical predictors of drug response in obsessive-compulsive disorder. J Clin Psychopharmacol. 2001;21(5):488-92.
9. Black DW, Monahan P, Gable J, Blum N, Clancy G, Baker P. Hoarding and treatment response in 38 nondepressed subjects with obsessive-compulsive disorder. J Clin Psychiatry. 1998;59(8):420-5.
10. Mataix-Cols D, Rauch SL, Manzo PA, Jenike MA, Baer L. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. Am J Psychiatry. 1999;156(9):1409-16.
11. Saxena S, Maidment KM, Vapnik T, Golden G, Rishwain T, Rosen RM, Tarlow G, Bystritsky A. Obsessive-compulsive hoarding: symptom severity and response to multimodal treatment. J Clin Psychiatry. 2002;63(1):21-7.
12. Alonso P, Menchon JM, Pifarre J, Mataix-Cols D, Torres L, Salgado P, Vallejo J. Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy. J Clin Psychiatry. 2001;62(7):535-40.
13. Ferrao YA, Shavitt RG, Bedin NR, de Mathis ME, Carlos Lopes A, Fontenelle LF, Torres AR, Miguel EC. Clinical features of refractory obsessive-compulsive patients. J Affective Disord. 2006;94:199-209.
14. Neziroglu FA, Stevens KP, Yaryura-Tobias JA. Overvalued ideas and their impact on treatment outcome. Rev Bras Psiquiatr. 1999;21(4):209-16.
15. Shavitt RG, Belotto C, Curi M, Hounie AG, Rosario-Campos MC, Diniz JB, Ferrao YA, Pato MT, Miguel EC. Clinical features associated with treatment response in obsessive-compulsive disorder. Compr Psychiatry. 2006;47(4):276-81.
16. Neziroglu F, Pinto A, Yaryura-Tobias JA, McKay D. Overvalued ideation as a predictor of fluvoxamine response in patients with obsessive-compulsive disorder. Psychiatry Res. 2004;125(1):53-60.
17. McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. Haloperidol addition in fluvoxamine-refractory Obsessive-Compulsive Disorder. Arch Gen Psychiatry. 1994;51(4):302-8.
18. McDougle CJ, Goodman WK, Price LH, Delgado PL, Krystal JH, Charney DS, Heninger GR. Neuroleptic addition in fluvoxamine-refractory Obsessive-Compulsive Disorder. Am J Psychiatr. 1990;147(5):652-4.
19. Minichiello WE, Baer L, Jenike MA. Schizotypical personality disorder: a poor prognostic indicator for behavioral therapy in the treatment of obsessive-compulsive disorder. J Anxiety Disord. 1987;1:273-6.
20. Baer L, Jenike MA, Black DW, Treece C, Rosenfeld R, Greist J. Effect of axis II diagnoses on treatment outcome with clomipramine in 55 patients with obsessive-compulsive disorder. Arch Gen Psychiatry. 1992;49(11):862-6.
21. Calvocoressi L, Lewis B, Harris M, Trufan S, Goodman WK, Mcdougle CJ, Price LH. Family accommodation in obsessive-compulsive disorder. Am J Psychiatry. 1995;152(3):441-3.
22. Steketee G, Van Noppen B. Family approaches to treatment for obsessive compulsive disorder. Rev Bras Psiquiatr. 2003;25(1):43-50
23. Steketee G, Lam JN, Chambless DL, Rodebaugh TL, McCullouch CE. Effects of perceived criticism on anxiety and depression during behavioral treatment of anxiety disorders. Behav Res Ther. 2007;45(1):11-9.
24. Greenberg BD, Pinto A, Mancebo M, Eisen J, Rasmussen SA. Obsessive-compulsive disorder: recognition across medical settings, and treatments from behavior therapy to neurosurgery. Med Health R I. 2006;89(5):162-5.
25. Koran L. Quality of life in Obsessive-Compulsive Disorder. Psych Clin North America. 2000;23(3):509-17.
26. Volpato Cordioli A, Heldt E, Braga Bochi D, Margis R, Basso de Sousa M, Fonseca Tonello J, Gus Manfro G, Kapczinski F. Cognitive-behavioral group therapy in obsessive-compulsive disorder: a randomized clinical trial. Psychother Psychosom. 2003;72(4):211-6.
27. Baer L, Minichiello WE. Internet assessment of obsessive-compulsive disorder. J Clin Psychiatry. 2006;67(9):1473.
28. Braga DT, Cordioli AV, Niederauer K, Manfro GG. Cognitive-behavioral group therapy for obsessive-compulsive disorder: a 1-year follow-up. Acta Psychiatr Scand. 2005;112(3):180-6.
29. Anderson RA, Rees CS. Group versus individual cognitive-behavioural treatment for obsessive-compulsive disorder: a controlled trial. Behav Res Ther. 2007;45(1):123-37.
30. Cordioli AV, Heldt E, Bochi DB, Margis R, Sousa MB, Tonello JF, Teruchkin B, Kapczinski F. Cognitive-behavioral group therapy in obsessive-compulsive disorder: a clinical trial. Rev Bras Psiquiatr. 2002;24(3):113-20.
31. McLean PD, Whittal ML, Thordarson DS, Taylor S, Söchting I, Koch WJ, Paterson R, Anderson W. Cognitive versus behavior therapy in the group treatment of obsessive-compulsive disorder. J Consult Clin Psychol. 2001;69(2):205-14.
32. Steketee G, Eisen J, Dyck I, Warshaw M, Rasmussen S. Predictors of course in obsessive-compulsive disorder. Psychiatry Res. 1999;89(3):229-38.
33. Prazeres AM, Souza WF, Fontenelle LF. Terapias de base cognitivo-comportamental do transtorno obsessivo-compulsivo: revisão sistemática da última década. Rev Bras Psiquiatr. 2007;29(3):262-70.
34. Calvocoressi L, McDougle CI, Wasylink S, Goodman WK, Trufan SJ, Price LH. Inpatient treatment of patients with severe obsessive-compulsive disorder. Hosp Community Psychiatry. 1993;44(12):1150-4.
35. Stewart SE, Yen CH, Stack DE, Jenike MA. Outcome predictors for severe obsessive-compulsive patients in intensive residential treatment. J Psychiatr Res. 2006;40(6):511-9.
36. Piacentini J, Bergman RL, Jacobs C, McCracken JT, Kretchman J. Open trial of cognitive behavior therapy for childhood obsessive-compulsive disorder. J Anxiety Disord. 2002;16(2):207-19.
37. Hofmann SG, Meuret AE, Smits JA, Simon NM, Pollack MH, Eisenmenger K, Shiekh M, Otto MW. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry. 2006;63(3):298-304.
38. Storch EA, Merlo LJ, Bengtson M, Murphy TK Lewis MH, Yang MC, Jacob ML, Larson M, Hirsh A, Fernandez M, Geffken GR, Goodman WK. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2007;22(4):230-7.
39. Jenike MA. Drug treatment of obsessive-compulsive disorder. In: Jenike MA, Baer L, Minichiello WE, editors. Obsessive-compulsive disorder - Practical management. 3rd edition. St Louis (MO): Mosby; 1998. p. 469-532.
40. Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Serlin RC. Efficacy and tolerability of serotonin transport inhibitors in obsessive compulsive disorder: a meta-analysis. Arch Gen Psychiatry. 1995;52(1):53-60.
41. Stein DJ, Spadaccini E, Hollander E. Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder. Int Clin Psychopharmacology. 1995;10(1):11-8.
42. Geller DA, Biederman J, Stewart SE, Mullin B, Martin A, Spencer T, Faraone SV. Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. Am J Psychiatry. 2003;160(11):1919-28.
43. Fontenelle LF, Nascimento AL, Mendlowicz MV, Shavitt RG, Versiani M. An update on the pharmacological treatment of obsessive-compulsive disorder. Expert Opin Pharmacother. 2007;8(5):563-83.
44. Fallon BA, Liebowitz MR, Campeas R, Schneier FR, Marshall R, Davies S, Goetz D, Klein DF. Intravenous clomipramine for Obsessive-Compulsive Disorder refractory to oral clomipramine. Arch Gen Psychiatry. 1998;55(10):918-24.
45. Pallanti S, Quercioli L, Koran LM. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. J Clin Psychiatry. 2002;63(9):796-801.
46. de Mathis MA, Diniz JB, do Rosario MC, Torres AR, Hoexter M, Hipolito GH, Miguel EC. What is the optimal way to subdivide obsessive-compulsive disorder? CNS Spectr. 2006;11(10):762-8.
47. Review: CNS Spect. 2006;11(10):771-4.
48. Review: CNS Spect. 2006;11(10):776-9.
49. Denys D, van der Wee N, Janssen J, De Geus F, Westenberg HG. Low level of dopaminergic D2 receptor binding in obsessive-compulsive disorder. Biol Psychiatry. 2004;55(10):1041-5.
50. Van der Wee NJ, Stevens H, Hardeman JA, Mandl RC, Denys DA, Van Megen HJ, Kahn RS, Westenberg HM. Enhanced dopamine transporter density in psychotropic-naive patients with obsessive-compulsive disorder shown by [123I]{beta}-CIT SPECT. Am J Psychiatry. 2004;161(12):2201-6.
51. Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 2006;11(7):622-32.
52. Bystritsky A, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry. 2004;65(4):565-8.
53. Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G. Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs). Psychopharmacol Bull. 1996;32(1):167-73.
54. Rosenberg DR, MacMillan SN, Moore GJ. Brain anatomy and chemistry may predict treatment response in paediatric obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2001;4(2):179-90.
55. Chakrabarty K, Bhattacharyya S, Christopher R, Khanna S. Glutamatergic dysfunction in OCD. Neuropsychopharmacology. 2005;30(9):1735-40.
56. Rauch SL. Neuroimaging and neurocircuitry models pertaining to the neurosurgical treatment of psychiatric disorders. Neurosurg Clin N Am. 2003;14(2):213-23.
57. Lopes AC, de Mathis ME, Canteras MM, Salvajoli JV, Del Porto JA, Miguel EC. Atualização sobre o tratamento neurocirúrgico do transtorno obsessivo-compulsivo. Rev Bras Psiquiatr. 2004;26(1):62-6.
58. Miguel EC, Lopes AC, Guertzenstein EZ, Calazas ME, Teixeira MJ, Brasil MA. Diretrizes para a neurocirurgia dos transtornos psiquiátricos graves no Brasil: uma proposta preliminar. Rev Bras Psiquiatr. 2004;26(1):8-9.
59. Mantovani A, Lisanby SH, Pieraccini F, Ulivelli M, Castrogiovanni P, Rossi. Repetitive transcranial magnetic stimulation (rTMS) in the treatment of obsessive-compulsive disorder (OCD) and Tourette's syndrome (TS). Int J Neuropsychopharmacol. 2006;9(1):95-100.
60. Greenberg BD, Malone DA, Friehs GM, Rezai AR, Kubu CS, Malloy PF, Salloway SP, Okun MS, Goodman WK, Rasmussen SA. Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder. Neuropsychopharmacology. 2006;31(11):2384-93.
61. Van Laere K, Nuttin B, Gabriels L, Dupont P, Rasmussen S, Greenberg BD, Cosyns, P. Metabolic imaging of anterior capsular stimulation in refractory obsessive-compulsive disorder: a key role for the subgenual anterior cingulate and ventral striatum. J Nucl Med. 2006;47(5):740-7.
62. Rauch SL, Dougherty DD, Malone D, Rezai A, Friehs G, Fischman AJ, Alpert NM, Haber SN, Stypulkowski PH, Rise MT, Rasmussen SA, Greenberg BD. A functional neuroimaging investigation of deep brain stimulation in patients with obsessive-compulsive disorder. J Neurosurgery. 2006;104(4):558-65.
63. Fodstad H, Strandman E, Karlsson B, West KA. Treatment of chronic obsessive compulsive states with stereotactic anterior capsulotomy or cingulotomy. Acta Neurochir (Wien). 1982;62(1-2):1-23.
64. Ruck C. Capsulotomy in anxiety disorders [thesis]. Stockholm: Karolinska University, Karolinska Institutet; 2006.
65. Braga DT, Cordioli AV, Niederauer K, Manfro GG. Cognitive-behavioral group therapy for obsessive-compulsive disorder: a 1-year follow-up. Acta Psychiatr Scand. 2005;112(3):180-6.
66. Li X, May RS, Tolbert LC, Jackson WT, Flournoy JM, Baxter LR. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. J Clin Psychiatry. 2005;66(6):736-43.
67. McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 2000;57(8):794-801.
68. Hollander E, Baldini Rossi N, Sood E, Pallanti S. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2003;6(4):397-401.
69. Thomsen PH. Risperidone augmentation in the treatment of severe adolescent OCD in SSRI-refractory cases: a case-series. Ann Clin Psychiatry. 2004;16(4):201-7.
70. Buchsbaum MS, Hollander E, Pallanti S, Baldini Rossi N, Platholi J, Newmark R, Bloom R, Sood E. Positron emission tomography imaging of risperidone augmentation in serotonin reuptake inhibitor-refractory patients. Neuropsychobiology. 2006;53(3):157-68.
71. McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 2000;57(8):794-801.
72. Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 2006;11(7):622-32. Erratum in: Mol Psychiatry. 2006;11(8):795.
73. Atmaca M, Kuloglu M, Tezcan E, Gecici O. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharmacol. 2002;17(3):115-9.
74. Denys D, de Geus F, van Megen HJ, Westenberg HG. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry. 2004;65(8):1040-8.
75. Carey PD, Vythilingum B, Seedat S, Muller JE, van Ameringen M, Stein DJ. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study. BMC Psychiatry. 2005;5:5.
76. Fineberg NA, Sivakumaran T, Roberts A, Gale T. Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study. Int Clin Psychopharmacol. 2005;20(4):223-6.
77. Shapira NA, Ward HE, Mandoki M, Murphy TK, Yang MC, Blier P, Goodman WK. A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry. 2004;55(5):553-5.
78. Bystritsky A, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry. 2004;65(4):565-8.
79. Marazziti D, Pfanner C, Dell'Osso B, Ciapparelli A, Presta S, Corretti G, Di Nasso E, Mungai F, Dell'Osso L. Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long-term open-label study. J Psychopharmacol. 2005;19(4):392-4.
80. Dannon PN, Sasson Y, Hirschmann S, Iancu I, Grunhaus LJ, Zohar J. Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial. Eur Neuropsychopharmacol. 2000;10(3):165-9.
81. Mundo E, Guglielmo E, Bellodi L. Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study. Int Clin Psychopharmacol. 1998;13(5):219-24.
82. Crockett BA, Churchill E, Davidson JR. A double-blind combination study of clonazepam with sertraline in obsessive-compulsive disorder. Ann Clin Psychiatry. 2004;16(3):127-32.
83. Pigott TA, L'Heureux F, Hill JL, Bihari K, Bernstein SE, Murphy DL. A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol. 1992;12(1):11-8.
84. McDougle CJ, Price LH, Goodman WK, Charney DS, Heninger GR. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol. 1991;11(3):175-84.
85. Pigott TA, Pato MT, L'Heureux F, Hill JL, Grover GN, Bernstein SE, Murphy DL. A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol. 1991;11(4):242-8.
86. Fux M, Benjamin J, Belmaker RH. Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind cross-over study. Int J Neuropsychopharmacol. 1999;2(3):193-5.
87. Koran LM, Aboujaoude E, Bullock KD, Franz B, Gamel N, Elliott M. Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2005;66(3):353-9.
88. Barr LC, Goodman WK, Anand A, McDougle CJ, Price LH. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Am J Psychiatry. 1997;154(9):1293-5.